DGAP-News: Eckert&Ziegler: Annual Net Profit Increases by 48%
(firmenpresse) - Eckert&Ziegler Strahlen- und Medizintechnik AG / Key word(s): Quarter Results
02.11.2010 07:45
---------------------------------------------------------------------------
Berlin, November 2, 2010 - Berlin-based Eckert&Ziegler Strahlen- und
Medizintechnik AG (ISIN DE0005659700), a firm specializing in medical use
of radioactivity, has again set new records for sales and profit in the
past quarter. For the first time in the history of the company, sales
reached EUR 28.2 million in a three-month period, an increase of approx.
11% over the same quarter in 2009. Profit doubled in comparison to the 3rd
quarter of 2009 to EUR 2.7 million, which corresponds to approx. EUR 0.52
per share.
In the first nine months of 2010, sales of EUR 81 million were achieved by
the Group, which is roughly EUR 3.2 million or 4% more than the same period
of the previous year. At the same time, profit after taxes and minority
interests increased by EUR 2.5 million or 48% to EUR 7.9 million. For the
nine-month period, earnings per share thus increased by 5% to EUR 1.51 per
share despite a 41% increase in the number of shares.
The most successful segment was once again Isotope Products (Industry).
Sales increased by 8%, the gross profit margin by 22% and the EBIT by 58%
(for comparison purposes, sales and income from the new Environmental
Services segment were once again added to the Isotope Products segment in
2010). The cause of the increases in income is primarily the successful
integration of Nuclitec, for which the restructuring expenses from the
previous year now no longer apply. The largest increase in sales was
achieved in the Isotrak division with the sale of reference and calibration
radiation sources.
With sales of EUR 22.4 million and an EBIT of EUR 3.6 million, the Therapy
segment also achieved a very good result in the first nine months of the
year, although the values were down from those of the same period in the
previous year by 6% in sales and 20% in EBIT. The reduced minority
interests after the IBt takeover bid had a distinctly positive effect.
While these interests amounted to 64% in the same period last year, only
32% of after-tax earnings were allocated to the minority shareholders of
IBt S.A. for accounting purposes in the first nine months of 2010. Complete
information about the Therapy segment can be found in the concurrently
released quarterly report of IBt S.A. (www.ibt-bebig.eu).
The Radiopharma segment was able to increase sales to EUR 15.9 million or
by 11% in comparison with the previous year while keeping costs nearly
constant. Extraordinary income of several hundred thousand euros from the
transfer of shares and borrowings of Eckert&Ziegler EURO-PET Berlin GmbH
was also included here. The cumulative EBIT of the segment rose by a total
of EUR 1.4 million to EUR 2.3 million in the first three quarters.
In the Environmental Services segment, which relates to taking back,
reprocessing, recycling and disposal of low level radioactive waste, no new
business was expected in the first six months of 2010, and with EUR 4.1
million in sales and expenses for preparations for new business that led to
a small loss of EUR 0.3 million, this area developed within the framework
of expectations.
The cash flow statement shows cash P&L earnings of EUR 16.0 million for the
first nine months of 2010, which is 20% over the corresponding value from
the previous year. In contrast to 2009, however, net current assets
increased by EUR 6.8 million. A cash inflow from operating activities of
EUR 9.2 million remains.
After the posting of the IBt takeover bid and the greatly increased
dividend payment in May 2010, the equity ratio again rose above 50% thanks
to the very high profit in the current year.
For the fiscal year 2010, the target for sales is EUR 105 million. The
Executive board is maintaining its profit forecast of EUR 9.5 million (EUR
1.80 per share). This target can be reached with proceeds from the
operating business without acquisitions.
The Eckert&Ziegler Group, with around 540 employees, is one of the
world's largest providers of isotope technology components for radiotherapy
and nuclear medicine.
If you have any questions, please contact:
Eckert&Ziegler AG, Karolin Riehle, Investor Relations,
Robert-Rössle-Str. 10, 13125 Berlin
Tel.: +49 (0) 30 / 94 10 84-138, Fax -112, E-mail: karolin.riehle(at)ezag.de,
www.ezag.de
02.11.2010 07:45 Dissemination of a Corporate News, transmitted by DGAP -
a company of EquityStory AG.
The issuer is solely responsible for the content of this announcement.
DGAP's Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Media archive at www.dgap-medientreff.de and www.dgap.de
---------------------------------------------------------------------------
Language: English
Company: Eckert&Ziegler Strahlen- und Medizintechnik AG
Robert-Rössle-Str.10
13125 Berlin
Deutschland
Phone: 49 30 941084-138
Fax: 49 30 941084-112
E-mail: karolin.riehle(at)ezag.de
Internet: www.ezag.de
ISIN: DE0005659700
WKN: 565970
Listed: Regulierter Markt in Frankfurt (Prime Standard), Stuttgart;
Freiverkehr in Hamburg, München, Düsseldorf, Berlin
End of Announcement DGAP News-Service
---------------------------------------------------------------------------
Datum: 02.11.2010 - 07:45 Uhr
Sprache: Deutsch
News-ID 32457
Anzahl Zeichen: 0
contact information:
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 231 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"DGAP-News: Eckert&Ziegler: Annual Net Profit Increases by 48%"
steht unter der journalistisch-redaktionellen Verantwortung von
Eckert&Ziegler Strahlen- und Medizintechnik AG (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
